Stanley Capital Management LLC boosted its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 21.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 188,500 shares of the specialty pharmaceutical company’s stock after purchasing an additional 33,200 shares during the period. Valeant Pharmaceuticals International accounts for about 2.1% of Stanley Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Stanley Capital Management LLC owned 0.05% of Valeant Pharmaceuticals International worth $3,261,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gruss & Co. Inc. acquired a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $104,000. Harbor Advisors LLC acquired a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $110,000. NEXT Financial Group Inc boosted its position in Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after purchasing an additional 600 shares during the last quarter. Financial Architects Inc boosted its position in Valeant Pharmaceuticals International by 10.5% during the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares during the last quarter. Finally, WMS Partners LLC acquired a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $116,000. 50.49% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 1.94% during trading on Wednesday, reaching $14.15. The company’s stock had a trading volume of 3,213,448 shares. The company’s market cap is $4.93 billion. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $28.59. The stock’s 50 day moving average is $14.78 and its 200 day moving average is $13.21.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the previous year, the firm posted ($0.88) EPS. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction on Monday, August 21st. The shares were acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 5.87% of the company’s stock.

Several brokerages recently commented on VRX. Guggenheim began coverage on Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They set a “buy” rating and a $18.00 price target for the company. Mizuho reissued an “underperform” rating and set a $8.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 20th. Royal Bank Of Canada reissued a “market perform” rating and set a $19.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 13th. Canaccord Genuity set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Thursday, August 10th. Finally, Rodman & Renshaw reissued a “neutral” rating and set a $17.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $17.62.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/13/stanley-capital-management-llc-buys-33200-shares-of-valeant-pharmaceuticals-international-inc-vrx.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.